Skip to main content

Dermatology

Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including: nipocalimab VAY736 (ianalumab) HZN-1116 AMG 329 R-2487 https://t.co/sVbyPLi2Um https://t.co/IlvthM7qyG
Dr. John Cush @RheumNow( View Tweet )
Patient info on Sweets Syndrome: acute febrile neutrophilic dermatosis https://t.co/0q93q2NVc9 https://t.co/cE3LA8LaRQ
Dr. John Cush @RheumNow( View Tweet )

EMR Messaging Woes (4.11.2025)

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com

Read Article
Metanalysis showed no increased risk of serious infx (SIE) w/ JAK inhibitors use in pts w/ immune-mediated inflammatory skin diseases -- 32 RCTs, 11,917 pts found SIE in 0.62% on JAKi vs 0.51% controls. Meta-analysis found no significant increase in risk of serious infection https://t.co/ugH72nk8bZ
Dr. John Cush @RheumNow( View Tweet )

An Epidural Letdown (4.4.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
EMA approved a record 28 biosimilars in 2024 for cancer, osteoporosis, macular degeneration, and immune-related diseases like plaque psoriasis, ulcerative colitis, and Crohn’s disease https://t.co/NNzKRalLvF https://t.co/nfX082a7ON
Dr. John Cush @RheumNow( View Tweet )

Cancer Survival with TNF Inhibitors (3.28.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article

Treating chronic inflammatory diseases with JAK inhibitors

Science Daily

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since their approval, the indications for these medical

Read Article

Axial Involvement in Psoriatic Arthritis

Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.

Read Article
Congratulations to Dr. Joseph Merola (Rheumatologists & Chair of Dermatology at UT Southwestern) on his appointment to the Board of Directors for the American Academy of Dermatology (AAD) https://t.co/TxjuZWeXoJ https://t.co/Mo7PwLWD5f
Dr. John Cush @RheumNow( View Tweet )

2024 Rheumatology Year in Review

2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians.  While these many advances offer new hope, they are countered by disappointments and gapping unmet needs in rheumatology. Below is my top 10 list

Read Article

Hydroxychloro-King (3.7.2025)

Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com

Read Article

Early Hydroxychloroquine Slows Cutaneous Lupus Progression

A prospective study of patients with limited cutaneous lupus erythematosus shows that early introduction of hydroxychloroquine may prevent progression to systemic lupus erythematosus.

Read Article
Misdiagnosis of Dermatomyositis JAMA Dermatology reports a retrospective cohort study from Johns Hopkins reviewing mimic of dermatomyositis (DM), suggesting that DM and especially clinically amyopathic DM (CADM) are commonly and initially misdiagnosed as inflammatory skin… https://t.co/2SbGxxcPLm https://t.co/TtoxFIXg3Q
Dr. John Cush @RheumNow( View Tweet )

Opioid Deaths are Down (2.28.2025)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week!

Read Article

Diagnoses via Immune ‘Fingerprints’

Science and researchers at Stanford Medicine have reported the use of Mal-ID (machine learning for immunological diagnosis) to analyze B and T cell receptors sequences from human blood, showing the ability to predict health status (healthy vs diseased) and discriminate between distinct

Read Article

CRP and Hidradenitis Supprativa

A post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II)  of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI. Adalimumab was equally effective in patients

Read Article

Deucravacitinib in Psoriasis - 5 Year Outcomes

BMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr. Marc Lebwohl at the Winter Clinical Dermatology Conference in Hawaii

Read Article
TheDaoIndex @KDAO2011 80% #hydradenitis suppurativa pts are smokers or former smokers, smoking can predate #HS by 4-5 years. Other associations: DM-2, Spa, obesity, SAPHO, PCOS eval for SCC (squ. cell CA) #RNL2025 https://t.co/XHrFseiAMK
Dr. John Cush @RheumNow( View Tweet )
Eric Dein @ericdeinmd How do you know if Morphea is active? -Erythema -Peripheral induration -New lesions in the past few month Non-active damage? - Dermal atrophy -SQ atrophy -Hyperpigmentation -Skin thickness center #RNL2025

Dr. John Cush @RheumNow( View Tweet )

Eric Dein @ericdeinmd #RNL2025 Treatment of sclerosing skin conditions: Active inflammation? Sclerotic? Atrophic? Target based on activity, depth of involvement and other disease involvement

Dr. John Cush @RheumNow( View Tweet )

Janet Pope @Janetbirdope #ClinicalPearl Insights into #fibrosing #skin conditions Inflammatory Fibrotic Atrophy We treat the #inflammation but need to determine if lesions are active or not Bx May not discern #dx Heidi Jacobe ⁦ #RNL2025 https://t.co/dG1k4fm4aO https://t.co/5TowCCDiTt
Dr. John Cush @RheumNow( View Tweet )

Valentine RNL 2025 Review (2.14.2025)

Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.

Read Article

“Preventing” Arthritis in Psoriasis

The always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.

Read Article
MDA5 + Pts with #ILD in #dermatomyositis can improve! ⁦@RheumNow⁩ ⁦@ACRheum⁩ #RNL2025 Data from Christina Charles-Schoeman #ClinicalPearl Her pearls 👇 #DM is a #vascular #disease #CK is not reliable in chronic DM Neg Abs don’t r/o #myositis https://t.co/hxomz70aq5
Janet Pope @Janetbirdope( View Tweet )
×